Biocept (BIOCQ) 10-Q2018 Q1 Quarterly report

Filed: 15 May 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: abstract, accrued, adapted, Agena, Anderson, Antonio, Astra, bevacizumab, Bioscience, brentuximab, Brownian, bundle, capability, Carlo, CDD, checkpoint, circumvent, Codification, comprised, conclusion, confirming, constrained, conversion, cooperation, correlate, correlation, count, customary, cycle, Dakota, Dawson, depict, dialogue, disaggregated, distinct, Empower, expedient, expiry, explanation, explicitly, expression, feasible, flat, forward, gathered, Geometric, Georgetown, germ, Giaccone, Giuseppe, guide, Gupta, half, hormone, identification, IHC, immunocytochemistry, immunohistochemistry, implied, indefinitely, Iowa, Kalinsky, Kevin, left, LM, loosen, marginal, Masonic, MD, MedStar, memo, Menarini, Minnesota, monotherapy, Monte, Motion, Natera, NGS, Notwithstanding, offshore, ovarian, pancreaticobiliary, Paper, passage, path, peripheral, point, poster, precision, reclassification, refractory, repatriated, repayment, robust, Shilpa, Similarly, simulation, solution, South, stranded, strongest, surgical, Sysmex, taxation, TC, TCTM, testicular, therapeutic, top, Translational, Treasury, unconstrained, unsatisfied, urge, vedontin, version, Wellmark, women, Zeneca

Removed: age, aged, agreed, amifampridine, Aspire, assumed, award, carcinoma, Catalyst, Claire, closely, committed, consummation, counterparty, derivative, Eaton, efficacy, eliminating, encompassed, enrolled, estimation, extension, Feltl, Firdapse, formed, goodwill, hepatocellular, impairment, Lambert, LIBOR, liver, Myasthenic, onset, ordinary, owner, partial, participated, partner, periodically, predictable, prescribing, realizable, record, recurrence, registering, reserve, reset, retail, retroactively, reverse, safety, screen, seasonality, shortening, simplifying, Specifically, split, Step, subsidiary, sum, Syndrome, trust, unavailable, underwriting

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated BIOCQ transcripts

BIOCQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION

I, Timothy Kennedy, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended March 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: May 15, 2018		/s/ Timothy Kennedy
		Timothy Kennedy
		Chief Financial Officer, Senior Vice President of Operations
		(Principal Financial and Accounting Officer)

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.